RXRX Quote, Financials, Valuation and Earnings

Amicus Therapeutics, Inc. has a net margin of -3135.32% compared to Recursion Pharmaceuticals, Inc.'s net margin of 10.24%. Recursion Pharmaceuticals, Inc.'s return on equity of -80.23% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.

Recursion Pharmaceuticals, Inc. has a consensus price target of $6.33, signalling upside risk potential of 35.91%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $15.90 which suggests that it could grow by 62.58%. Given that Amicus Therapeutics, Inc. has higher upside potential than Recursion Pharmaceuticals, Inc., analysts believe Amicus Therapeutics, Inc. is more attractive than Recursion Pharmaceuticals, Inc..

Recursion Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.675%.

Recursion Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Recursion Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Recursion Pharmaceuticals, Inc. quarterly revenues are $5.2M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Recursion Pharmaceuticals, Inc.'s net income of -$162.3M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Recursion Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Recursion Pharmaceuticals, Inc. is 42.75x versus 5.00x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Hims & Hers Health, Inc. has a net margin of -3135.32% compared to Recursion Pharmaceuticals, Inc.'s net margin of 2.63%. Recursion Pharmaceuticals, Inc.'s return on equity of -80.23% beat Hims & Hers Health, Inc.'s return on equity of 25.63%.

Recursion Pharmaceuticals, Inc. has a consensus price target of $6.33, signalling upside risk potential of 35.91%. On the other hand Hims & Hers Health, Inc. has an analysts' consensus of $44.82 which suggests that it could grow by 20.9%. Given that Recursion Pharmaceuticals, Inc. has higher upside potential than Hims & Hers Health, Inc., analysts believe Recursion Pharmaceuticals, Inc. is more attractive than Hims & Hers Health, Inc..

Recursion Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Hims & Hers Health, Inc. has a beta of 2.414, suggesting its more volatile than the S&P 500 by 141.424%.

Recursion Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hims & Hers Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Recursion Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Hims & Hers Health, Inc. pays out -- of its earnings as a dividend.

Recursion Pharmaceuticals, Inc. quarterly revenues are $5.2M, which are smaller than Hims & Hers Health, Inc. quarterly revenues of $599M. Recursion Pharmaceuticals, Inc.'s net income of -$162.3M is lower than Hims & Hers Health, Inc.'s net income of $15.8M. Notably, Recursion Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Hims & Hers Health, Inc.'s PE ratio is 68.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Recursion Pharmaceuticals, Inc. is 42.75x versus 4.16x for Hims & Hers Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -3135.32% compared to Recursion Pharmaceuticals, Inc.'s net margin of 31.72%. Recursion Pharmaceuticals, Inc.'s return on equity of -80.23% beat Eli Lilly & Co.'s return on equity of 106.26%.

Recursion Pharmaceuticals, Inc. has a consensus price target of $6.33, signalling upside risk potential of 35.91%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,045.59 which suggests that it could grow by 1.16%. Given that Recursion Pharmaceuticals, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Recursion Pharmaceuticals, Inc. is more attractive than Eli Lilly & Co..

Recursion Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Recursion Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.58% to investors and pays a quarterly dividend of $1.50 per share. Recursion Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Recursion Pharmaceuticals, Inc. quarterly revenues are $5.2M, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Recursion Pharmaceuticals, Inc.'s net income of -$162.3M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Recursion Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 51.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Recursion Pharmaceuticals, Inc. is 42.75x versus 15.86x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -3135.32% compared to Recursion Pharmaceuticals, Inc.'s net margin of 21.32%. Recursion Pharmaceuticals, Inc.'s return on equity of -80.23% beat Pfizer Inc.'s return on equity of 10.84%.

Recursion Pharmaceuticals, Inc. has a consensus price target of $6.33, signalling upside risk potential of 35.91%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 13.57%. Given that Recursion Pharmaceuticals, Inc. has higher upside potential than Pfizer Inc., analysts believe Recursion Pharmaceuticals, Inc. is more attractive than Pfizer Inc..

Recursion Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Recursion Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.73% to investors and pays a quarterly dividend of $0.43 per share. Recursion Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Recursion Pharmaceuticals, Inc. quarterly revenues are $5.2M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Recursion Pharmaceuticals, Inc.'s net income of -$162.3M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Recursion Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Recursion Pharmaceuticals, Inc. is 42.75x versus 2.32x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.